RSS

cancer

A collaboration between IONTAS, a company focused on the discovery and optimisation of fully human antibodies, and IGEM Therapeutics, an immunologist-oncology company, for the identification of novel IgE antibodies for cancer targets. more

News

Boehringer Ingelheim and Vanderbilt University have expanded their partnership to develop novel anti-cancer drugs that inhibit the myeloid cell leukaemia 1 (MCL1) protein, which is highly prevalent in many difficult to treat cancers. more

News

A consortium has been launched by Certara for the development of a quantitative systems pharmacology immune-oncology simulator to test combination cancer therapies and different dose regimens and biomarkers in computer-generated, virtual patients more

News

A drug that specifically targets tropomyosin receptor kinases (TRK) fused genes, larotrectinib, has been found to be effective in patients of all ages, according to recently published results from combined analysis. more

News

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. more

News

NHS funded initiative, SBRI Healthcare, has revealed its latest round of development awards, with 10 companies set to share a £1 million investment to develop innovations for high potential cancer screening solutions. more

News

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication more

News

The US Food and Drug Administration (FDA) has approved a treatment for a type of cancer that affects the pancreas or gastrointestinal tract — gastroenteropancreatic neuroendocrine tumors (GEP-NETs). more

News

NHS England has revealed that thousands of patients have benefited from the new CDF and as a result of discounts it has secured on eight treatments, savings of around £140 million should be generated over the course of the next five years more

News

Monoclonal antibodies (MAb) solutions are a major class of biopharmaceuticals with various applications. They are important for treating diseases such as cancer, inflammation, allergies, infectious diseases and cardiovascular diseases. more

A new strategy to tackle the issue of long-term treatment efficacy in cancer patients has been developed by researchers from the Netherlands Cancer Institute in collaboration with international biotechnology company, Genmab. more

News

Developer of placenta-based cell therapy products, Pluristem Therapeutics, has revealed that its PLX cells have been shown to significantly inhibit cancer cell growth in a recently published peer-reviewed article. more

News

Clinical-stage biopharmaceutical company, Autolus, has presented data for its pan-checkpoint blocking technology at the American Society of Hematology (ASH) annual meeting in Atlanta. more

News

Global provider of advanced delivery technologies and development solutions, Catalent, and clinical-stage biotechnology company, Vaccinex, have signed an agreement for the development of an antibody drug conjugate (ADC) to be used against cancer more

News

The US Food and Drug Administration (FDA) has approved the first biosimilar for the treatment of certain breast and stomach cancers, Ogivri (trastuzumab-dkst). more

News

Molecular diagnostics company, Biocartis, has signed a companion diagnostic (CDx) development agreement with biotechnology company, Amgen, for the Idylla RAS biomarker tests. more

News

An international prize worth £350,000 has been awarded to an expert in tissue engineering and regenerative medicine (TERM) by the Institution of Engineering and Technology (IET). more

News

Cancer researchers are excited by new work that is indicating a cheap, over-the-counter cold remedy (N-Acetyl cysteine, or NAC) can inhibitor the tumour stroma — a cell compartment that is fundamental to the spread of cancer. more

News

Alderley Park has been confirmed as the interim home for the Cancer Research UK (CRUK) Manchester Institute, underlining it as a key asset in the North of England. more

News

Biopharmaceutical company, Tesaro, has revealed that the European Commission has approved its monotherapy for the maintenance treatment of women with recurrent ovarian cancer. more

News